AzTrials
AzTrials

Rokitansky SyndromeMRKHNCT01911884

Assessment of Quality of Global and Sexual Life and Impact of Surgical and Non Surgical Vaginal Aplasia in Patients With a Rokitansky Syndrome

A study testing evaluate quality of life of surgical and non surgical vaginal aplasia in people with Rokitansky Syndrome and Surgical or Vaginal Dilatation of Vaginal Aplasia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The principal objective is to assess the general health status and the sexual health status of women with Rokitansky syndrome having received a surgical or non surgical treatment. The secondary purpose is to assess the anatomical aspect and the quality of sexual life. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
evaluate quality of life of surgical and non surgical vaginal aplasia
Could I receive a placebo?
No, everyone receives an active treatment
How many people
138 participants
Where
1 siteFrance
Study dates
11 Oct 2012to 10 Apr 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient affected with Rokitansky syndrome
  • Patient over 18 years old
  • Patient care with dilatations or by surgery since 1995
  • Patient having started dilatations or having had surgery since at least one year
  • Patient who signed the consent
  • French patient
  • Women with social welfare

Who cannot join

  • Patient with a serious chronic disease interfering with analysis to be performed in this project.
  • Patient can't reading or writing
  • Patient with legal protection

Trial locations and contacts

1 site in 1 country.

France1 site
  • Service d'Endocrinologie et Gynécologie Pédiatriques Hôpital Necker Enfants Malades

    Paris, 75015

Other trials in France

About this study

The principal objective is to assess the general health status and the sexual health status of women with Rokitansky syndrome having received a surgical or non surgical treatment.

The secondary purpose is to assess the anatomical aspect and the quality of sexual life. To search a correlation between the anatomical result, the general and sexual quality of life. To compare the different techniques of medical follow-up in terms of anatomic results, general quality of life, sexual quality of life, complications and morbidities.

Read more

To evaluate social inclusion of these women with their family situation, social and professional category and their job.

At the same time, we propose an evaluation with a psychologist to study the impact of the announcement of the diagnosis. This impact study is conducted at a distance from diagnosis.

Read the detailed description

The MRKH syndrome is a congenital disorder characterized by absence of uterus and at least the two thirds of the vagina, a female phenotype and a normal karyotype XX.

These patients have normal ovaries and fallopian tubes. The external genitalia are normal. This syndrome was described by Mayer (1829), Rokitansky ( 1838), Kuster ( 1910) and Hauser ( 1961). About one in every 4500 female babies has this condition. This syndrome represents 85% of congenital vagina aplasia and is the second cause of primary amenorrhea after disorders of sexual development. These women are unfertile.

The malformation can be isolated or associated with other malformations called MURCS (Müllerian duct aplasia, renal aplasia, and cervicothoracic somite dysplasia), as kidney ( 30%), bone ( 10%) or cardiac malformations ( 1%).

The most common age for MRKH to be diagnosed is when the woman hasn't started her period ( 85%).Some girls may find out at an earlier age when there is a severe malformation , during a systematic gynaecological examination or during an pelvic ultrasound. When the women are older, the syndrome can be diagnosed during studies for infertility.

A pelvic ultrasound is usually the first test performed to assess presence of uterus. A magnetic resonance imaging may be used to complete the investigations. These tests can also confirm if there are two ovaries and two kidneys. Sometimes, a very small uterus can be seen, it's a uterine horn.

The psychological management is essential to take care of the women affected.It seeks to understand the impact of the diagnosis announcement and the various treatments offered. The follow-up can be different for each girl and her parents during several appointments.

Therapeutic management can be proposed when the girl is ready because the therapeutic is long and difficult. Two therapeutic approaches can be proposed: to create a vagina using dilators or having a surgical procedure. In France, vaginal reconstruction with dilators is the most used. This method consists in dilating the vagina progressively with different sizes of dilators in order to obtain a vaginal opening of 8 cm around 6 months after treatment initiation. This method is successful in about 75% of cases. Complications are exceptional.

Surgery is an option for patients who are unsuccessful with dilatators or patients who prefer surgery. A number of operations are appropriate for the correction of vaginal agenesis. Vecchietti procedure and sigmoid vaginoplasty are the most commonly used techniques in France.

In national and international publications, it is impossible to compare scientifically the results of the different technique because of the small effective in each studies and because of the the lack of standardized assessment. Studies report the functional result for each technique but none compare the techniques used. No studies compared the result in terms of anatomical and function results, complications and quality of life.

The demonstration of a positive correlation between the anatomic criteria and the functional results would help to guide the surgical technique. The lack of correlation would suggest that a perfect anatomical reconstruction is not essential. If it is demonstrated, the management should focus on other criteria like psychological management. Several factors seem to influence the general and sexual quality of life of women affected by the Rokitansky syndrome. Our objective is to evaluate the importance of these factors to improve the treatment of these women.

Being tested
evaluate quality of life of surgical and non surgical vaginal aplasia
Keywords
Rokitansky syndrome, surgical or vaginal dilatation of vaginal aplasia, quality of global and sexual life
Medical subject headings
Mullerian aplasia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • evaluate quality of life of surgical and non surgical vaginal aplasiaBehavioural

    protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia

Study groups in NCT01911884
Study groupRoleWhat they receive
Patients with a Rokitansky SyndromeOtherPatients with a Rokitansky Syndrome
Receives: Behavioral: evaluate quality of life of surgical and non surgical vaginal aplasia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of quality of global life

    To fill a self-administered questionnaire: the World Health Organization Quality Of Life (general scale WHOQOL)

    Measured: Day 0

Secondary outcomes (3)
  1. Assessment of quality of sexual life

    To fill 2 self-administered questionnaires : Female Sexual Function Index and Female Sexual Dysfunction Scale-Revised (FSFI and FSDS)

    Measured: Day 0

  2. Assessment of anatomic results

    Gynaecological examination

    Measured: Day 0

  3. Assessment of social integration

    To fill a self-administered questionnaire (marital status, occupational group, education level, employment status)

    Measured: Day 0

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jul 2013 (estimated)
  2. Study start11 Oct 2012
  3. Primary completion10 Apr 2015
  4. Study completion10 Apr 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
138 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01911884
Sponsor's protocol ID
P110124
Other IDs
ID RCB : 2011-A01517-34
Acronym
MRKH
Status last verified
Aug 2025
First submitted
26 Jul 2013
Last updated
5 Sep 2025
Results posted
No
Data monitoring committee
No

Publications

  • Cheikhelard A, Bidet M, Baptiste A, Viaud M, Fagot C, Khen-Dunlop N, Louis-Sylvestre C, Sarnacki S, Touraine P, Elie C, Aigrain Y, Polak M; French MRKH Study Group. Surgery is not superior to dilation for the management of vaginal agenesis in Mayer-Rokitansky-Kuster-Hauser syndrome: a multicenter comparative observational study in 131 patients. Am J Obstet Gynecol. 2018 Sep;219(3):281.e1-281.e9. doi: 10.1016/j.ajog.2018.07.015. Epub 2018 Jul 21.

    PubMed 30036500

Questions about this trial

What is this clinical trial studying?

A study testing evaluate quality of life of surgical and non surgical vaginal aplasia in people with Rokitansky Syndrome and Surgical or Vaginal Dilatation of Vaginal Aplasia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of quality of global life (time frame: Day 0). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01911884, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in